NewPhase Clinical Trials has an established history of working with many pharmaceutical companies, including Allergan, Amgen, AstraZeneca, Bausch & Lomb, Bayer, Boehringer-Ingelheim, Britol-Myers Squibb, Covance, Eli Lilly, GlaxoSmithKline, Gilead Sciences, Icon, Integrium, Merck, Nipro, Novartis, Johnson & Johnson, Pfizer and Takeda Pharmaceutical, among others. 


​CURRENT STUDIES:


A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin  Sanofi 2016


Evolocumab Study: Getting to an imprOved Understanding of LDL-C and Dyslipidemia management (GOULD): a Registry of High Cardiovascular Risk Patients in the United States  Amgen 2016


Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) AKB-6548-CI-0014 AKEBIA 2016

A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial with a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered with Dapagliflozin Compared to Insulin Glargine in Subjects with Type 2 Diabetes who have inadequate Glycemic Control on Metformin with or without Sulfonylurea Therapy.  CV181369. 2015   Sub-I

Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) AKB-6548-CI-0015 AKEBIA 2015

A 52 Week, Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess The Efficacy, Safety and Tolerability of PF-04950615 In Subjects with Primary Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events. B1481045. Pfizer 2015.  P.I.

A 26-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3b Trial with a Blinded 26-Week Long-Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered with Dapagliflozin in Combination with Metformin Compared to Sitagliptin in Combination with Metformin in Adult Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone.  CV181363. 2015  Sub-I

A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compare with the Addition of Glimepiride in Subjects with Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control on Metformin. MK8835-002. MERCK 2014. P.I.

START-CKD: Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease. (Darbepoetin Alfa) 20110226. Amgen  2012. Sub-I

RECENTLY CLOSED STUDIES:


ALERTS (AngelMed for Early Recognition and Treatment of STEMI) Study. Device Study.  Angel Med 2010. Sub-I


Phase III Trial to Confirm the Anti-Angina Effect of T89 in Patients with Stable Angina (CAESA Study). T89-07 CAESA. Tasly Pharmaceuticals. Sub-I

An Evaluation of Tissue Engineering Approaches for Treatment of Neuropathic Diabetic Foot Ulcers Resistant to Standard of Care: A Prospective, Randomized Controlled Trial. ACL2011-002-H. ACell. Sub-I

A 52 Week, Phase III Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of PF-04950615 in Subjects with Heterozygous Familial Hypercholesterolemia. B1481021. Pfizer Sub-I

Randomized, Parallel-Group, Double-Blind, Vehicle-Controlled Phase III Clinical Trials to Evaluate the Effectiveness of DSC127 in Treating Non-Healing Diabetic Foot Ulcer (“DFU”). DSC127-2012-02 Sub-I

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Comparator-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects with Type 2 Diabetes Mellitus with Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy. MK8835-001. Merek P.I.

CARDIOVASCULAR

If you have Dyslipidemia and are a high risk for cardiovascular disease you may qualify for clinical trial.

KIDNEY:

If you have anemia due to chronic kidney disease and are either on dialysis or not on dialysis, you may qualify for clinical trial.

  • Diabetes    
  • Cardiovascular
  • Liver    
  • Podiatry    
  • Medical Device     
  • Women's Health    
  • Hypertension
  • Men's Health
  • Hyperlipidemia

DIABETES:
Have you been diagnosed with Diabetes?

If you are controlling your sugar levels with exercise and diet only, you may qualify for a clinical trial!

Clinical Trial Studies We Specialize In

clinical trials research Studies

For Information:

(305) 858-4300

​Research Studies